PSCP, a novel reactive sulfur donor, activates Keap1-Nrf2 signaling and attenuates mitochondrial dysfunction in

Kexin Li1, Ruiying Ji1, Youbang Chen1

  • 1Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.

PubMed
Abstract

Insights

Diabetic retinopathy (DR) involves poorly understood molecular drivers. This study identified IDH2 and MGST1 as key targets and showed PSCP protects mitochondria by activating the Keap1-Nrf2 pathway, offering therapeutic potential for DR.

Area of Science:

  • Ophthalmology
  • Diabetology
  • Molecular Biology

Background:

  • Diabetic retinopathy (DR) is a major cause of vision loss in diabetes.
  • The molecular mechanisms underlying DR pathogenesis are not fully understood.
  • Identifying novel therapeutic targets is crucial for managing DR.

Purpose of the Study:

  • To identify stress-responsive molecular targets in diabetic retinopathy.
  • To investigate the therapeutic potential of PSCP, a reactive sulfur donor, in DR.
  • To elucidate the role of the Keap1-Nrf2 pathway in DR.

Main Methods:

  • Analysis of retinal transcriptomic datasets from diabetic mouse models (type 1 and type 2).
  • Induction of oxidative and carbonyl stress in ARPE-19 cells using H2O2 or MGO.
  • Assessment of mitochondrial function, gene expression, and antioxidant pathways with PSCP and Nrf2 inhibitor ML385.

Main Results:

  • IDH2 and MGST1 were identified as dysregulated mitochondrial antioxidant enzymes in diabetic retinas.
  • Oxidative and carbonyl stress impaired mitochondrial function and cell viability, suppressing IDH2 and MGST1.
  • PSCP treatment restored IDH2, MGST1, and mitochondrial dynamics by activating the Keap1-Nrf2 pathway, an effect blocked by ML385.

Conclusions:

  • IDH2 and MGST1 are critical stress-responsive mitochondrial targets in diabetic retinopathy.
  • PSCP demonstrates therapeutic potential by activating the Keap1-Nrf2 pathway to protect mitochondrial integrity.
  • Targeting the Keap1-Nrf2 pathway offers a promising strategy for treating diabetic retinopathy.